Keywords
corticosteroids
covid-19
rhizopus
rhino-orbital cerebral mucormycosis
How to Cite
Abstract
Abstract
This case series explores Covid-19 associated Mucormycosis (CAM), its risk factors, clinical features and outcomes from a tertiary centre in Maharashtra, India, during the second wave of COVID-19.
Methods: A retrospective, observational case series of 104 consecutive patients admitted to the hospital at various stages of complications of CAM, during the second wave of the COVID-19 pandemic (Jan’21-Apr’21). The diagnosis was confirmed using Potassium hydroxide wet mount (KOH), histopathology, fungal culture, and Cone-Beam Computed Tomography(CBCT).
Results: There were 81% men, mean age of 49 ± 12.4 years, and all patients had a history of corticosteroids usage, 82% had a prior diagnosis of diabetes mellitus (DM) and the rest were newly diagnosed. Diagnosis of mucormycosis was confirmed on 2 modalities in 71%; KOH and histopathology in 31 (30%), and fungal culture with KOH and histopathology together detected 25 (24%). 9% were diagnosed exclusively with CBCT. Patients with prior DM had higher morbidity OR 8.30 [95% CI: 2.12, 32.5; p=0.002] and mortality OR 13.23 [95% CI: 1.67, 104.7; p=0.014] than non-DM patients. Mortality was higher in patients with rhino + orbital involvement than patients with rhino + maxillary involvement [OR 8.37 [95% CI: 1.52, 46.09; p=0.014].
Conclusion: Diabetes remained the highest risk factor for the development of CAM in patients with COVID-19 on corticosteroids, with high mortality and morbidity. Timely medical and surgical interventions and multi-disciplinary approaches could potentially reduce mucormycosis-associated mortality. Among the diagnostic modalities, detection using CBCT may increase the diagnostic yield in patients not detected in other modalities.
References
India's COVID-19 Emergency. The Lancet. 2021.
Alimohamadi Y. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020; 61:3-E304.
Chakrabarti A. The recent mucormycosis storm over Indian sky. Indian J Med Microbiol. 2021; 39:269-270.
Jose A, Singh S, Roychoudhury A, Kholakiya Y, Arya S, Roychoudhury S. Current Understanding in the Pathophysiology of SARS-CoV-2-Associated Rhino-Orbito-Cerebral Mucormycosis: A Comprehensive Review. Journal of Maxillofacial and Oral Surgery. 2021; 20:373-380.
Suvvari T, Arigapudi N, Kandi V, Kutikuppala L. Mucormycosis: A killer in the shadow of COVID-19. Journal of Medical Mycology. 2021; 31:101161. vol. 31, p.
Honavar, Sen S, Mrittika, Sengupta, Sabyasachi Rao, Raksha, et al. J Ophthalmol. 1:1670.
Alba-Loureiro T, Munhoz C, Martins J, Cerchiaro G, Scavone C, Curi R et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Brazilian Journal of Medical and Biological Research. 2007;40(8):1037-1044.
Peleg A, Weerarathna T, McCarthy J, Davis T. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes/Metabolism Research and Reviews. 2006;23(1):3-13.
Davis H, Assaf G, Mccorkell L, Wei, Hannah, Low R, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. Clin Med. 2021; 38:101019.
Rodriguez Morales A, Sah R, Millan-Oñate J, Gonzalez A, Montenegro-Idrogo J, Scherger S, et al. COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs. Ther Adv Infect Dis. 2021; 8:204993612110270.
Selarka L, Sharma S, Saini D, Sharma S, Batra A, Waghmare V, et al. Mucormycosis and COVID‐19: An epidemic within a pandemic in India. Mycoses. 2021; 64: 1253-1260.
Jenks J, Reed S, Seidel D, P Koehler, O Cornely, S Mehta et al. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Int. J. Antimicrob. Agents. 2018; 52:706-712.
Manzur-Pineda K, O’neil C, Bornak A, Lalama M, Shao T, Kang N, et al. COVID-19-related thrombotic complications experience before and during delta wave .J. Vasc. Surg. 2022; 76:1374-1382.e1.
Wu C T, Lidsky P, Xiao Y, Lee I, Cheng R, Nakayama T, et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metab. 2021; 33:1565-1576.e5.
Hu B, Huang S, Yin L. The cytokine storm and COVID‐19.J. Med. Virol. 2020; 93:250-256.
Hussman J. Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention.Front. Pharmacol. 2020; 11.
Berbudi A, Rahmadika N, Tjahjadi A, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. Curr Diabetes Rev. 2020; 16:442-449.
Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. The Journal of Laryngology & OtologY. 2021; 135:442-447.
Saidha P, Kapoor S, Das P, Gupta A, Kakkar V, Kumar A, et al. Mucormycosis of Paranasal Sinuses of Odontogenic Origin Post COVID-19 Infection: A Case Series. Indian Journal of Otolaryngology and Head & Neck Surgery. 2021.
Dave T, Gopinathan Nair A, Hegde R, Vithalani N, Desai S, Adulkar N, et al. Clinical Presentations, Management and Outcomes of Rhino-Orbital-Cerebral Mucormycosis (ROCM) Following COVID-19: A Multi-Centric Study. Ophthalmic Plast Reconstr Surg. 2021; 37:488-495.
Ramphul K, Verma, Renuka, Kumar, Nomesh, Ramphul, et al. Petras Rising concerns of Mucormycosis (Zygomycosis) among COVID-19 patients; an analysis and review based on case reports in the literature. Acta Biomedica Atenei Parmensis. 2021; 92:e2021271.
Sherwani S, Khan H, Ekhzaimy A, Masood A, Sakharkar M. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark. Insights. 2016; 11:BMI.S38440.
Fard H, Mahmudi-Azer S, Sefidbakht S, Iranpour P, S Bolandparvaz, Abbasi H, et al. Evaluation of Chest CT scan as a screening and diagnostic tool in trauma patients with coronavirus disease 2019 (COVID-19): a cross-sectional study in southern Iran. Emerg Med Int. 2021:1–8.
Jeong W, Keighley C, Wolfe R, Lee W, Slavin M, Kong D, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin. Microbiol. Infect. 2019; 25:26-34.
Desai S, Gujarathi-Saraf A, Agarwal E. Imaging findings using a combined MRI/CT protocol to identify the “entire iceberg” in post-COVID-19 mucormycosis presenting clinically as only “the tip”. Clin Radiol. 2021; 76:784.e27-784.e33.
Verma D, Bali R. COVID-19 and Mucormycosis of the Craniofacial skeleton: Causal, Contributory or Coincidental? Journal of Maxillofacial and Oral Surgery. 2021; 20:165-166.
Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y, et al. The microbial coinfection in COVID-19. Appl. Microbiol. Biotechnol. 2020; 104:7777-7785.
Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus. 2020; 12:e10726.
Marques AP, Perrella A, Arita ES, Pereira MF, Cavalcanti Mde. Assessment of simulated mandibular condyle bone lesions by cone beam computed tomography. Brazilian Oral Research. 2010;24(4):467–74.
Patel A, Tee BC, Fields H, Jones E, Chaudhry J, Sun Z. Evaluation of cone-beam computed tomography in the diagnosis of simulated small osseous defects in the mandibular condyle. American Journal of Orthodontics and Dentofacial Orthopedics. 2014;145(2):143–56.
Katakami K, Shimoda S, Kobayashi K, Kawasaki K. Histological investigation of osseous changes of mandibular condyles with backscattered electron images. Dentomaxillofacial Radiology. 2008;37(6):330–9.
Miloglu O, Yilmaz AB, Yildirim E, Akgul HM. Pneumatization of the articular eminence on cone beam computed tomography: Prevalence, characteristics and a review of the literature. Dentomaxillofacial Radiology. 2011;40(2):110–4.
Sulewski A, Sieroʼn, Dominik, Szyluk, Karol, Dąbrowski, et al. In Andreas Avascular Necrosis Bone Complication after Active COVID-19 Infection: Preliminary Results. Medicina, 2021; 57: 1211–1311.
Badakere A, Patil-Chhablani P, Orbital Apex Syndrome: A Review. Eye and brain. 2019; 11:63–72.
Pagare. Diagnostic Role of CBCT in Fulminating Mucormycosis of Maxilla. International Journal of Research and Review. 2019; 6:575–579.
Cornely O, Alastruey-Izquierdo A, Arenz D, Chen S, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. 2019; 19:e405-e421.
Lanternier F, Poiree S, Elie C, Garcia-Hermoso D, Bakouboula P, Sitbon K, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J. Antimicrob. Chemother. 2015; 70:3116-3123.
Cornely O, Alastruey-Izquierdo A, Arenz D, Chen S, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. 2019; 19:e405-e421.
Noor A, Preuss C, Amphotericin B. StatPearls [Internet]. Treasure Island. 2022.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Array